By contrast, the Myc-CaP model, which originates from a Myc-driven adenocarcinoma, retains androgen receptor (AR) expression and signaling, making it an ideal model for studying AR-driven prostate cancers, which remain a major therapeutic challenge due to their heterogeneous responses to RPT and immunotherapy. This evidence concerns the gene MYC and Familial prostate cancer.